OncoMatch/Clinical Trials/NCT06633354
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Is NCT06633354 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CD5 CAR T-cells for t-acute lymphoblastic leukemia.
Treatment: CD5 CAR T-cells — A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-ALL
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD5 overexpression (>90%)
CD5 expression rate was >90%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
No CR after standard chemotherapy; The first induction reaches CR, but CR ≤ 12 months; Patients with r/r CD5+T-ALL have not responded to the first or multiple remedial treatments; Multiple recurrences.
Cannot have received: gene therapy
Before using any gene therapy products
Cannot have received: systemic corticosteroids
Exception: glucocorticoid physiological replacement therapy, such as prednisone < 10 mg/d or equivalent
treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone < 10 mg/d or an equivalent dose of the drug)
Cannot have received: small molecule targeted therapy
received within 72 hours of small molecule targeted therapy
Cannot have received: systemic chemotherapy
Exception: pretreatment
2 weeks received systemic chemotherapy except (pretreatment)
Cannot have received: radiation therapy
four weeks received radiotherapy
Lab requirements
Kidney function
creatinine ≤176.8 (mol/L)
Liver function
Total bilirubin ≤51 (mol/L), ALT/AST ≤ 3x ULN
Cardiac function
LVEF ≥50%
Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L); Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06633354 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy, systemic corticosteroids, small molecule targeted therapy disqualifies patients from enrollment.
Does this trial require CD5?
Yes, CD5 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages